Targeted therapy uses drugs to find and attack cancer cells. You may have this treatment on its own or with chemotherapy.
The main type of targeted therapy used to treat non-Hodgkin lymphoma (NHL) is a drug called rituximab. Rituximab belongs to a group of targeted therapies call monoclonal antibodies. It works by encouraging the body’s immune system to attack and destroy the lymphoma cells.
Rituximab may be given on its own or in combination with chemotherapy.
For some types of NHL, rituximab treatment continues after the lymphoma is in remission. The aim is to keep the lymphoma away for as long as possible. It may be given every 2 to 3 months for up to 3 years, or for as long as it is keeping the lymphoma in remission. This is called maintenance treatment.
We have more information about rituximab. This includes how the drug is given and possible side effects.
People with some rarer types of NHL may have other types of targeted therapy as part of their treatment.
Other types of targeted therapy are being developed. They may be used to treat lymphoma as part of a clinical trial.
This type of treatment is not often used to treat Hodgkin lymphoma.
Some people have a targeted therapy called rituximab to treat nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). Another drug called brentuximab vedotin (Adcetris®) may be used as part of the treatment for classical Hodgkin lymphoma that has come back. Sometimes targeted therapy drugs are given as part of a clinical trial to treat Hodgkin lymphoma.